The bill defines “chemical or surgical mutilation” to include puberty blockers, cross‑sex hormones, and surgical procedures intended to change an individual’s physical appearance or reproductive function away from their sex. It prohibits health care professionals, hospitals, and clinics from participating in such interventions on anyone under 18 when an interstate‑commerce connection exists and creates a private federal cause of action for injured children or their parents with compensatory, non‑economic, and punitive damages.
This is significant because the statute federalizes a zone of pediatric medical practice through an interstate‑commerce basis for jurisdiction, imposes strict liability for post‑enactment interventions, shifts burdens of proof for narrow exceptions to providers, and extends a long litigation window (up to 25 years after an affected child’s 18th birthday). Hospital counsel, pediatric specialists, insurers, and compliance officers need to evaluate documentation, consent practices, and coverage exposure immediately if the bill’s definitions would capture their care models.
At a Glance
What It Does
The bill defines prohibited interventions broadly (puberty blockers, sex hormones, surgeries) and makes it unlawful for health care professionals, hospitals, or clinics to participate in those interventions on minors when an interstate‑commerce nexus exists. It establishes a private federal civil remedy with compensatory, non‑economic, and punitive damages and imposes strict liability for post‑enactment participation.
Who It Affects
Pediatric endocrinologists, pediatric surgeons, adolescent medicine clinics, hospitals with pediatric programs, insurers that cover gender‑related care, and parents and children who have received or contemplate such care. Plaintiffs’ attorneys and litigation funders are also directly affected by the new cause of action.
Why It Matters
The bill uses commerce‑clause connections to reach medical practice that states commonly regulate, changes how courts will treat prevailing standards of care in disputed fields, and raises immediate malpractice and regulatory compliance risks for providers and payers involved with gender‑related care for minors.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Chloe Cole Act defines a narrow but consequential set of interventions as “chemical or surgical mutilation”: any use of puberty blockers (including GnRH agonists), sex hormones (estrogen, testosterone, androgen blockers, progesterone), or surgeries intended to alter or remove sexual organs or to shift physical appearance away from the individual’s sex. The bill also defines “participate” broadly to include prescribing, administering, authorizing, coordinating, or supervising such care.
The statute excludes treatments for recognized disorders of sexual development, infections or injuries caused by prior interventions, and care intended to reverse or remediate prior interventions (detransition treatment).
The prohibition applies only when an interstate or foreign commerce connection exists; the bill lists multiple triggers (travel, use of channels of interstate commerce, payments or communications across state lines, use of items that traveled in interstate commerce, or when the procedure occurs in federal jurisdictions). Where a provider claims an exclusion applies, the provider must prove that exception by clear and convincing evidence.
For interventions after enactment, providers are strictly liable if their participation is proven by clear and convincing evidence.The Act creates a private federal right of action for any individual subjected to a covered intervention as a child and for their parents or guardians, with damages available for economic costs to correct or ameliorate effects, non‑economic harms, and punitive damages upon a high showing of malicious or reckless conduct. The cause of action applies to interventions performed before or after enactment; the statute of limitations allows suit up to 25 years after the victim’s 18th birthday or within 4 years of incurring the cost of detransition treatment, whichever is later.
Separately, the bill says counseling, referrals, and informational discussions do not create liability unless they rise to the level of participation.Practically, hospitals and clinicians who treat gender‑related conditions in minors will need to reassess their protocols: documenting any reliance on a statutory exclusion to a clear‑and‑convincing standard, tracking the interstate elements that could trigger federal jurisdiction, and evaluating malpractice and insurance exposure given strict liability and available punitive awards. The bill also changes litigation dynamics by limiting deference to prevailing standards of care where those standards were in ‘‘serious, scientific, and medical dispute’’ at the time of care, which could expose past care in contested specialties to retrospective challenge.
The Five Things You Need to Know
The bill makes providers strictly liable for any covered participation in chemical or surgical interventions on minors that occurs after enactment if proven by clear and convincing evidence.
Federal jurisdiction is triggered by a broad list of interstate‑commerce connections (travel, payments, communications, use of items that moved in interstate commerce, or care performed in federal territories or D.C.).
A private federal civil action may be brought by the person treated as a child or that person’s parents or guardians, and the claim applies regardless of whether the procedure occurred before or after enactment.
Damages include economic costs to undo or ameliorate procedures, non‑economic damages for pain and suffering, and punitive damages upon clear and convincing proof of malicious, intentional, fraudulent, or reckless conduct.
The statute of limitations is the later of 25 years from the individual’s 18th birthday or 4 years from when detransition treatment costs are incurred.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the statute the 'Chloe Cole Act.' This section is purely stylistic but signals the bill’s focus and will appear in statutory citations and codified headings.
Key definitions (chemical or surgical mutilation, sex, participate, etc.)
This is the operational core: it defines 'chemical or surgical mutilation' to include puberty blockers, sex hormones, and surgical attempts to change sexual organs or appearance, but carves out DSD treatment, care for infections or injuries caused by prior interventions, certain organ system conditions, and detransition treatment. 'Participate' covers prescribing, administering, performing, authorizing, supervising, or coordinating those interventions. The bill also defines 'sex' as an immutable biological classification determined at conception, which will matter in later disputes about whether a specific procedure 'alters' sex.
Prohibition and interstate‑commerce triggers; burden for exceptions
Makes it unlawful for health care professionals, hospitals, or clinics to participate in covered interventions on children when one of several interstate‑commerce connections exists and requires that any claimed statutory exception be proven by clear and convincing evidence before participation can commence. The subsection lists seven alternative jurisdictional hooks, making federal jurisdiction potentially broad — a single cross‑state payment, telecommunication, or use of an item from interstate commerce could invoke the federal prohibition.
Private right of action, damages, and strict liability
Creates a federal civil remedy available to the child or their parents for covered interventions regardless of timing (before or after enactment). It authorizes compensatory damages tied to correction or remediation costs, non‑economic damages for emotional harm, and punitive damages on a clear‑and‑convincing showing of malice or recklessness. The section also imposes strict liability for participation occurring after enactment and places the burden of proving an exception on the defendant by the same clear‑and‑convincing standard.
Rules of construction — counseling, waiver, ambiguity, deference
Clarifies that counseling, referrals, and discussion of options do not, by themselves, create liability unless they rise to the level of prohibited participation; it bans contractual waiver of a provider’s liability; resolves ambiguities against a party found to have participated; and restricts deference to prevailing standards of care where those standards were in serious scientific dispute at the time of treatment. These rules change how courts will approach expert testimony, standard‑of‑care arguments, and informed‑consent practices.
Statute of limitations
Permits claims within 25 years of the injured individual’s 18th birthday or within 4 years of when detransition costs are incurred, whichever is later. That extended window creates long tail exposure for institutions and clinicians and requires record retention and forensic review capabilities for care given to minors.
Severability
Standard severability clause stating that if one provision is held unconstitutional the remaining provisions remain in force. It preserves the remainder of the statute against partial judicial invalidation.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Children subjected to covered interventions and their parents: They gain a federal civil remedy with compensatory and non‑economic damages and the ability to recover costs to correct or ameliorate treatment effects.
- Providers of detransition care and clinicians treating DSD: The statute explicitly excludes detransition treatment and medically necessary DSD care, protecting those services from the ban and supporting demand for remediation services.
- Plaintiffs’ attorneys and litigation funders: The creation of a federal cause of action with long statutes of limitations and potential punitive damages creates new litigation opportunities and market demand for plaintiff representation.
- Advocacy organizations and civil‑litigation groups aligned with restrictions on pediatric gender care: They acquire a federal enforcement tool and a framework for recruiting and supporting plaintiffs.
Who Bears the Cost
- Pediatric endocrinologists, surgeons, adolescent medicine clinics, and hospitals: They face increased malpractice and civil exposure, must tighten documentation, may alter clinical practices, and could see chilling effects on care delivery.
- Professional liability insurers and health plans: Insurers may face higher defense and indemnity costs, tighten coverage terms, or increase premiums for institutions and clinicians who provide the affected care.
- Hospital risk managers and compliance departments: They will absorb compliance, training, record‑keeping, and litigation‑avoidance costs, and may need to develop new protocols to document any claimed statutory exceptions by clear and convincing evidence.
- Medical societies and credentialing bodies: They may incur reputational and regulatory costs defending prevailing standards of care that the statute invites courts to scrutinize when 'serious scientific and medical dispute' is alleged.
- Federal courts and defense resources: The new private right of action, long limitation window, and interstate hooks are likely to produce multi‑jurisdictional litigation and administrative burdens on the judiciary and public defenders for indigent defendants.
Key Issues
The Core Tension
The central dilemma is between protecting minors from irreversible medical interventions and preserving clinicians’ ability to exercise medical judgment under state licensing and professional standards: the bill prioritizes a precautionary, rights‑based protectionist approach enforced by federal civil liability, while that enforcement mechanism risks supplanting local medical regulation, chilling legitimate care, and triggering constitutional and evidentiary disputes over the proper scope of federal authority and standards of proof.
The bill’s legal reach depends on two contested elements: the statutory definition of 'sex' (determined at conception) and the multiple interstate‑commerce triggers. Both create litigation levers: plaintiffs can point to a single cross‑state payment, telehealth exchange, or supply item to establish federal jurisdiction.
That construction effectively federalizes conduct many states regulate, making medical practice variations across states a litigation risk rather than a regulatory choice.
Second, the bill imposes strict liability for post‑enactment acts and forces providers to prove narrow exceptions by clear and convincing evidence. That combination is unusual in medical torts and will shift clinical decision‑making toward defensive documentation and away from discretionary judgments.
The statute limits deference to prevailing standards of care when those standards were 'in serious, scientific, and medical dispute,' which invites retrospective re‑examination of past practice and creates uncertainty about what contemporaneous professional consensus will mean in court. Finally, the bill’s text leaves open difficult evidentiary questions — how to prove the requisite intent to 'alter' an individual’s body, how to assess causation for long‑term developmental effects, and how insurers and hospitals will underwrite liability that can reach back decades.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.